The Financial Times reports Gilead Sciences' coronavirus drug failed its first randomized clinical trial. Yahoo Finance’s Anjalee Khemlani joins Seana Smith to discuss....
While Wedbush sees a difficult short-term trajectory for Apple Inc. (NASDAQ: AAPL), the sell-side firm said Thursday that Cupertino is staying on track with the launch schedule for its flagship product, the iPhone. The Apple Analyst Daniel Ives maintained an Outperform rating on Apple with a $335 price target. What's Known About The iPhone 12 Apple is likely working on four iPhone 12 models, with a mix of 4G and 5G phones that are likely to be launched between October and early December, just in time for the holiday season, Ives said in a Thursday note, citing supply chain checks in Asia. (See his track record here.)The analyst said he expects two versions of 5G phones, U.S. and non-U.S., with the U.S. version likely to have mmWave technology that could push out the production timeline.Many units could therefore be shifted to the March quarter, he said. Muted Expectations For Apple's Q2...
Johns Hopkins Biocontainment Unit medical director Dr. Brian Garibaldi warns that reopening the economy now puts the U.S. at risk of going "right back where we were in that panic state a month ago.”...
